Treating failing sight and hearing may lower dementia risk — the evidence is uneven

Losing your sight or hearing in old age is linked to a higher risk of dementia, and correcting it is now on the list of things that might reduce that risk. The evidence for this is real but uneven. An observational study tied cataract surgery to about a 29% lower risk of developing dementia [s1]. Yet the largest randomised trial of hearing aids found no overall effect on cognitive decline [s2]. That gap — a strong association on one side, a null trial on the other — is the honest state of a field that is often oversold.

This summarises research findings; it is not advice about surgery or hearing aids, which are decisions for a person and their clinician on their own merits, quite apart from any dementia question.

Why senses and cognition are linked

The idea is biologically plausible and now embedded in mainstream dementia thinking. The 2024 Lancet Commission on dementia lists 14 modifiable risk factors that together could theoretically delay or prevent 45% of cases, and its two newest additions were untreated vision loss and high LDL cholesterol [s3]. Vision loss, the Commission noted, has a more pronounced effect on risk in late life, from age 65 [s3]. Hearing loss has featured as a leading modifiable factor for longer. Proposed mechanisms include the extra cognitive load of straining to see or hear, reduced stimulation, and social withdrawal — the same pathways that make sensory loss a driver of isolation and of hospital delirium.

The strongest vision signal

The most cited vision study drew on the Adult Changes in Thought cohort, following 3,038 older adults who had a diagnosis of cataract or glaucoma [s1]. Over 23,554 person-years, cataract extraction was associated with a significantly lower risk of dementia than not having the surgery (hazard ratio 0.71, 95% confidence interval 0.62 to 0.83; P<0.001) [s1].

What makes this more than an ordinary correlation is the study's built-in control. Glaucoma surgery, which does not restore vision, showed no association with dementia risk (HR 1.08, 95% CI 0.75 to 1.56) [s1]. If the benefit were simply that healthier people get more operations, glaucoma surgery should have looked protective too; it did not. That the effect tracked the surgery that actually restores sight strengthens the case that vision itself, not surgical selection, is doing the work. The participants were on average 74 at their first cataract diagnosis, and the association held after the authors used marginal structural models to account for the probability of surgery and an extensive list of confounders — a serious attempt to rule out the "healthy-patient" bias that dogs this kind of research [s1]. Still, this is an observational study, not a randomised trial, and cannot prove cause.

The hearing trial that complicates the story

Hearing is where the strongest test exists, and it is sobering. The ACHIEVE trial randomised older adults with hearing loss to a hearing intervention or a health-education control and measured cognitive change over three years [s2]. Across the whole trial, the difference between the groups was negligible — the hearing intervention did not slow cognitive decline overall, examined in detail in our coverage of the ACHIEVE result. A pre-specified subgroup at higher risk did appear to benefit, which is hypothesis-generating rather than conclusive.

The contrast matters. Observational data consistently link hearing loss to dementia, and correcting hearing is sensible for hearing's sake — see the evidence on over-the-counter hearing aids. But the one large randomised trial did not show that treating it protects cognition across the board, which is the claim that observational associations invite and cannot themselves establish.

How to read this

Treating sensory loss is worthwhile on its own terms — for sight, hearing, safety and independence. Whether it also prevents dementia is genuinely unsettled: the vision evidence is suggestive but observational, and the best hearing trial was null overall. The framing that "fixing your eyes and ears wards off dementia" runs ahead of the data, even as sensory loss earns its place among the modifiable risk factors the Lancet Commission highlights.

What to watch

The open question is causal: randomised trials of vision correction with cognitive endpoints, and longer follow-up of the hearing trials. Until those report, sensory treatment should be pursued for the senses, with any dementia benefit treated as a plausible bonus rather than a promise.